Ruibing Wang received his B.S. degree in chemistry from Jilin University (Changchun, China) in 2002 and his Ph.D. degree in organic chemistry from Queen’s University (Kingston, ON, Canada) in 2007. Due to the excellence of his Ph.D. research, his thesis was entitled “The outstanding thesis award by Queen’s School of Graduate Studies.” He continued in the same laboratory as a Postdoctoral Fellow at Queen’s University (2007-2008) and then moved to the Steacie Institute for Molecular Sciences at the National Research Council of Canada as a Research Associate for about two years, where he worked on nanomaterial development and studied their applications in solar cell and bioimaging. In late 2009, he became a Senior R&D Scientist in the field of nuclear medicine, medical devices, and radiopharmaceutical development at Nordion Inc., and subsequently Wang joined BTG plc together with the Targeted Therapies Division of Nordion due to acquisition of TheraSphere by BTG for 200 million US dollars in July 2013. At Nordion/BTG, he had led Bexxar support and TheraSphere development and innovation projects as a Senior Scientist. Very recently, he has joined the University of Macau as an Assistant Professor in the area of pharmaceutical sciences and healthcare product development. His research and development activities have been mainly focused on the research and development of novel medical devices (such as microparticles and nanomedicine) and interventional medicine for cancer diagnostics and therapeutics, and these may include supramolecular formulation and nanoformulation or microparticle formulation of active drug components and/or therapeutic isotopes for targeted delivery and controlled drug release.
Biography Updated on 21 July 2015